Filing Details
- Accession Number:
- 0001209191-21-002317
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-01-06 18:25:56
- Reporting Period:
- 2021-01-04
- Accepted Time:
- 2021-01-06 18:25:56
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1708493 | Harpoon Therapeutics Inc. | HARP | Biological Products, (No Disgnostic Substances) (2836) | 473458693 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1763592 | Holger Wesche | C/O Harpoon Therapeutics, Inc. 131 Oyster Point Boulevard, Suite 300 South San Francisco CA 94080 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-01-04 | 10,000 | $0.60 | 62,852 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-01-04 | 3,100 | $17.32 | 59,752 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-01-04 | 3,351 | $18.30 | 56,401 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-01-04 | 3,549 | $19.39 | 52,852 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2021-01-04 | 10,000 | $0.00 | 10,000 | $0.60 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 11,006 | 2027-01-13 | No | 4 | M | Direct |
Footnotes
- Includes 183 shares acquired under the Employee Stock Purchase Plan on September 30, 2020.
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- Represents the weighted average sales price per share. The shares sold at prices ranging from $16.8831 to $17.86 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- Represents the weighted average sales price per share. The shares sold at prices ranging from $17.89 to $18.75 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- Represents the weighted average sales price per share. The shares sold at prices ranging from $19.00 to $19.78 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- The stock options are part of a grant that vested and became exercisable as to 25% of the shares subject to the option grant on May 24, 2017, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the options are 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
Billionaire Hedge Funds
